Bcl-2-like protein-10 increases aggressive features of melanoma cells.
B-cell lymphoma-2-like protein-10
invasion
melanoma
migration
vasculogenic mimicry
Journal
Exploration of targeted anti-tumor therapy
ISSN: 2692-3114
Titre abrégé: Explor Target Antitumor Ther
Pays: United States
ID NLM: 101770662
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
09
2021
accepted:
20
12
2021
pubmed:
2
9
2022
medline:
2
9
2022
entrez:
1
9
2022
Statut:
ppublish
Résumé
B-cell lymphoma-2 (Bcl-2)-like protein-10 (Bcl2L10) is the less studied member of Bcl-2 family proteins, with the controversial role in different cancer histotypes. Very recently, Bcl2L10 expression in melanoma tumor specimens and its role in melanoma response to therapy have been demonstrated. Here, the involvement of Bcl2L10 on the Endogenous Bcl2L10 protein expression was detected by western blotting analysis in a panel of patient-derived and commercially available human melanoma cells. Results demonstrated that Bcl2L10 acts as an inducer of Overall, data reported in this paper provide evidence supporting a positive role of Bcl2L10 in melanoma aggressive features.
Identifiants
pubmed: 36046354
doi: 10.37349/etat.2022.00068
pii: etat-03-100268
pmc: PMC9400776
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11-26Informations de copyright
© The Author(s) 2022.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.